Related Experiment Video

Updated: Dec 21, 2025

A Methodological Approach to Non-invasive Assessments of Vascular Function and Morphology
09:33

A Methodological Approach to Non-invasive Assessments of Vascular Function and Morphology

Published on: February 7, 2015

16.7K

Evaluation of atherogenic laboratory markers in Behçet's disease patients with vascular involvement

Çiğdem Yücel1, Ahmet Omma2, Erdim Sertoğlu3

  • 1Department of Clinical Biochemistry, Ankara Numune Training and Research Hospital, Altındağ, Ankara, Turkey.

Archives of Medical Science : AMS
|May 14, 2020
PubMed

Insights

Elevated homocysteine, tumor necrosis factor-alpha (TNF-α), and Lp-pla2 levels may help diagnose vascular involvement in Behçet's disease patients. These inflammatory and atherogenic markers show significant differences in affected individuals.

Area of Science:

  • Rheumatology and Immunology
  • Vascular Biology and Medicine
  • Biomarker Discovery

Background:

  • Behçet's disease is a chronic inflammatory vasculitis characterized by immunological and endothelial dysfunction.
  • Identifying reliable diagnostic markers for vascular involvement in Behçet's disease is crucial for patient management.

Purpose of the Study:

  • To evaluate and compare blood levels of various diagnostic markers in Behçet's disease patients, with a focus on those with vascular involvement.
  • To identify potential biomarkers indicative of vascular complications in Behçet's disease.

Main Methods:

  • A cohort of 50 Behçet's disease patients (22 with vascular involvement) and 30 healthy controls were analyzed.
  • Blood levels of hsCRP, ESR, TNF-α, apoA1, apoB, HDL, LDL, triglyceride, total cholesterol, Lp-plA-2, homocysteine, and IMA were measured.
  • Statistical analysis was performed to compare marker levels between patient groups and controls.

Main Results:

  • Significant differences in hsCRP, TNF-α, homocysteine, IMA, apoA1, apoB, HDL, Lp-pla2, and ESR were observed between Behçet's patients and healthy controls.
  • Behçet's patients with vascular involvement exhibited significantly higher levels of homocysteine, TNF-α, and Lp-pla2 compared to those without vascular involvement.

Conclusions:

  • Elevated inflammatory and atherogenic markers are expected in Behçet's disease due to its inflammatory nature.
  • Increased homocysteine, TNF-α, and Lp-pla2 levels show promise as candidate diagnostic tools for assessing vascular involvement in Behçet's disease patients.
Abstract

Keywords:
Behçet’s diseaseatherosclerosisinflammationvascular involvement

More Related Videos

Assessment of Vascular Function in Patients With Chronic Kidney Disease08:50

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

16.6K
On-Chip Endothelial Inflammatory Phenotyping12:43

On-Chip Endothelial Inflammatory Phenotyping

Published on: July 21, 2012

11.3K

Related Concept Videos

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
363
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
253
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
437
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
336
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
647
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
261